ES2805326T3 - Coagonistas estables del receptor de GLP-1/glucagón basados en GLP-1 - Google Patents

Coagonistas estables del receptor de GLP-1/glucagón basados en GLP-1 Download PDF

Info

Publication number
ES2805326T3
ES2805326T3 ES15778311T ES15778311T ES2805326T3 ES 2805326 T3 ES2805326 T3 ES 2805326T3 ES 15778311 T ES15778311 T ES 15778311T ES 15778311 T ES15778311 T ES 15778311T ES 2805326 T3 ES2805326 T3 ES 2805326T3
Authority
ES
Spain
Prior art keywords
glp
amino
ethoxy
derivative
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15778311T
Other languages
English (en)
Spanish (es)
Inventor
Steffen Reedtz-Runge
Ulrich Sensfuss
Thomas Kruse
Jane Spetzler
Henning Thøgersen
Tornøe Christian Wenzel
Jesper F Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2805326T3 publication Critical patent/ES2805326T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES15778311T 2014-10-10 2015-10-09 Coagonistas estables del receptor de GLP-1/glucagón basados en GLP-1 Active ES2805326T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14188421 2014-10-10
PCT/EP2015/073372 WO2016055610A1 (en) 2014-10-10 2015-10-09 Stable glp-1 based glp-1/glucagon receptor co-agonists

Publications (1)

Publication Number Publication Date
ES2805326T3 true ES2805326T3 (es) 2021-02-11

Family

ID=51663097

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15778311T Active ES2805326T3 (es) 2014-10-10 2015-10-09 Coagonistas estables del receptor de GLP-1/glucagón basados en GLP-1

Country Status (7)

Country Link
US (1) US9988430B2 (enExample)
EP (1) EP3204408B1 (enExample)
JP (1) JP2017536343A (enExample)
CN (1) CN107108713A (enExample)
ES (1) ES2805326T3 (enExample)
TW (1) TW201629095A (enExample)
WO (1) WO2016055610A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR102608220B1 (ko) 2016-05-06 2023-11-29 아이오니스 파마수티컬즈, 인코포레이티드 Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
JP6601578B2 (ja) * 2017-07-13 2019-11-06 不二製油グループ本社株式会社 ペプチド
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023044290A1 (en) 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
US20090209469A1 (en) * 2006-08-04 2009-08-20 Dennis Kim Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
WO2009030738A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN102075337A (zh) 2009-11-20 2011-05-25 腾讯科技（深圳）有限公司 一种即时通信消息显示方法和相关装置
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BR112012018104A2 (pt) 2010-01-20 2017-10-17 Zeland Pharma As tratamento de doenças cardíacas
BR112012024379A2 (pt) 2010-03-26 2017-01-10 Novo Nordisk As "peptídeos glucagon, seu uso, bem como composição farmacêutica"
MA34383B1 (fr) * 2010-06-24 2013-07-03 Zealand Pharma As Analogues de glucagon
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2013041678A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
BR112016016321A2 (pt) 2014-02-18 2017-10-03 Novo Nordisk As Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica

Also Published As

Publication number Publication date
WO2016055610A1 (en) 2016-04-14
JP2017536343A (ja) 2017-12-07
EP3204408A1 (en) 2017-08-16
TW201629095A (zh) 2016-08-16
EP3204408B1 (en) 2020-05-06
CN107108713A (zh) 2017-08-29
US20160102129A1 (en) 2016-04-14
US9988430B2 (en) 2018-06-05

Similar Documents

Publication Publication Date Title
ES2805326T3 (es) Coagonistas estables del receptor de GLP-1/glucagón basados en GLP-1
CN105307672B (zh) 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
US10570184B2 (en) GLP-1/glucagon receptor co-agonists for medical use
JP6352806B2 (ja) 新規のグルカゴン類似体
CN102918055B (zh) 新的胰高血糖素类似物
CN103596583B (zh) 新型胰高血糖素类似物
CN102933598A (zh) 新型胰高血糖素类似物
CA2939763A1 (en) Stable glucagon analogues and use for treatment of hypoglycaemia
ES2754048T3 (es) Coagonistas de receptores de GLP-1/glucagón prolongados y estables para uso médico
ES2767705T3 (es) Nuevos análogos de glucagón
ES2834127T3 (es) Derivados de GLP-1, y sus usos